{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:46:02Z","timestamp":1787013962325,"version":"build-2736575974"},"reference-count":70,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Purpose<\/jats:title>\n                    <jats:p>The limited effectiveness of current pharmacological treatments for alcohol use disorder (AUD) highlights the need for novel therapies. These may involve the glucagon\u2010like peptide\u20101 receptor or the amylin receptor, as treatment with agonists targeting either of these receptors lowers alcohol intake. The complexity of the mechanisms underlying AUD indicates that combining agents could enhance treatment efficacy. While a combination of amylin receptor and GLP\u20101 receptor agonists reduced food intake and body weight synergistic\u2010like, its influence on alcohol intake is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Approach<\/jats:title>\n                    <jats:p>\n                      Effects of a range of dose\u2010combinations of GLP\u20101 receptor (dulaglutide) and amylin receptor (salmon calcitonin; sCT) agonists on alcohol intake were explored in male and female rats. We used dose combinations that either lowered alcohol intake as monotherapy (0.1\u2009mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u2009+\u20095\u2009\u03bcg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      ), or that did not affect alcohol consumption\n                      <jats:italic>per se<\/jats:italic>\n                      (0.075\u2009mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u2009+\u20092\u2009\u03bcg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>\n                      Acute administration of dulaglutide and sCT (0.1\u2009mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u2009+\u20095\u2009\u03bcg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) reduced alcohol intake in males, but not in females. When higher doses were evaluated in female rats, a decrease in alcohol intake was observed. Furthermore, the low dose combination (0.075\u2009mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u2009+\u20092\u2009\u03bcg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) decreased, in in a synergistic\u2010like manner, alcohol intake and prevented abstinence\u2010induced drinking without affecting kaolin intake in males. However, tolerance developed during sub\u2010chronic treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Implications<\/jats:title>\n                    <jats:p>Collectively, these findings show that the combination of dulaglutide and sCT decreased, in in a synergistic\u2010like manner, alcohol consumption in male rats. Contrarily, higher doses are required for females.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bph.17406","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T19:34:26Z","timestamp":1733168066000},"page":"1292-1305","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Synergistic\u2010like decreases in alcohol intake following combined pharmacotherapy with GLP\u20101 and amylin in male rats"],"prefix":"10.1111","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5325-1667","authenticated-orcid":false,"given":"Cajsa","family":"Aran\u00e4s","sequence":"first","affiliation":[{"name":"Institute of Neuroscience and Physiology, Department of Pharmacology The Sahlgrenska Academy at the University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Caffrey","sequence":"additional","affiliation":[{"name":"Department of Biobehavioral Health Sciences, School of Nursing University of Pennsylvania  Philadelphia Pennsylvania USA"},{"name":"Department of Psychiatry, Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian E.","family":"Edvardsson","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Department of Pharmacology The Sahlgrenska Academy at the University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Vestlund","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Department of Pharmacology The Sahlgrenska Academy at the University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heath D.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Biobehavioral Health Sciences, School of Nursing University of Pennsylvania  Philadelphia Pennsylvania USA"},{"name":"Department of Psychiatry, Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Jerlhag","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Department of Pharmacology The Sahlgrenska Academy at the University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16177"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1180512"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104642"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.685631"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00275.2010"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2015.12.007"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101444"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.4c00133"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00344-4"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109686"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31775-1"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249710"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15868"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2012.11.009"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091936"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6997(25)06847-4"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.5772\/63144"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.013"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.11.005"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2019.146562"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2006.00002.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049557"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3628"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0323-x"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12603"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12910"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12910"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.12.022"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2021.113541"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-62619-6.00003-3"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00678-2"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.149"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44591-8"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15178"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.11.005"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijosup.2016.4"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(95)02067-5"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(99)00208-9"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00297.2007"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803284"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04054.x"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.66"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000410"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48267-2"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-016-0059-9"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m15068"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2006.00012.x"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.20882\/adicciones.708"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061965"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2008.00753.x"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12807"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13199"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020070068"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.68"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.ph0919s72"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1092828"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00923-1"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad040"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084348"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01401"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100746"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13776"},{"issue":"1","key":"e_1_2_12_67_1","first-page":"5","article-title":"Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon\u2010Like Peptide 1 (GLP\u20101) Receptor Agonists for Substance Use Disorders","volume":"85","author":"Bremmer M. P.","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.04.004"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1089\/met.2018.0075"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20070993"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14153"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.17406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:44:26Z","timestamp":1739234666000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.17406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/bph.17406"],"URL":"https:\/\/doi.org\/10.1111\/bph.17406","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"2024-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}